Endocyte Inc (ECYT) financial statements (2020 and earlier)

Company profile

Business Address 3000 KENT AVE STE A1-100
WEST LAFAYETTE, IN 47906
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments97138174125123176
Cash and cash equivalents193115465334
Short-term investments791071588070142
Receivables000166
Prepaid expense12113
Prepaid expense and other current assets3
Other current assets00010
Total current assets:99140175127133185
Noncurrent Assets
Property, plant and equipment233443
Long-term investments and receivables   822626
Long-term investments   822626
Other noncurrent assets00000
Prepaid expense and other noncurrent assets1
Total noncurrent assets:234863029
TOTAL ASSETS:101143178213163214
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3454108
Accounts payable011154
Accrued liabilities  1122
Employee-related liabilities333332
Debt     0
Deferred revenue and credits   06052
Other liabilities   00 
Other undisclosed current liabilities211242
Total current liabilities:56677462
Noncurrent Liabilities
Long-term debt and lease obligation     0
Capital lease obligations     0
Liabilities, other than long-term debt1111152
Deferred revenue and credits1111152
Other liabilities 0000 
Total noncurrent liabilities:1111152
Total liabilities:567875115
Stockholders' equity
Stockholders' equity attributable to parent9513717120588100
Common stock000000
Additional paid in capital404391381374262255
Accumulated other comprehensive income (loss)(0)(0)(0)(0)00
Accumulated deficit(309)(254)(210)(168)(174)(156)
Total stockholders' equity:9513717120588100
TOTAL LIABILITIES AND EQUITY:101143178213163214

Income statement (P&L) ($ in millions)

12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
Revenues000706535
Revenue, net  053137
Cost of revenue
(Cost of Goods and Services Sold)
    (52)(28)
Gross profit:00070137
Operating expenses(56)(45)(42)(65)(83)(51)
Other undisclosed operating income    5228
Operating income (loss):(56)(45)(42)5(18)(16)
Nonoperating income (expense)0(0)000(1)
Investment income, nonoperating   100
Other nonoperating income (expense)0(0)0(0)(0)(1)
Interest and debt expense   (0)(0)(2)
Income (loss) before gain (loss) on sale of properties:(56)(45)(42)5(18)(18)
Other undisclosed net income1     
Net income (loss):(55)(45)(42)5(18)(18)
Other undisclosed net income (loss) attributable to parent 11(0) 1
Net income (loss) available to common stockholders, diluted:(55)(44)(41)5(18)(17)

Comprehensive Income ($ in millions)

12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
Net income (loss):(55)(45)(42)5(18)(18)
Other comprehensive income (loss)  0(0)(0) 
Comprehensive income (loss):(55)(45)(42)5(18)(18)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)11(0) 1
Comprehensive income (loss), net of tax, attributable to parent:(55)(44)(41)5(18)(17)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: